Kalvista Pharmaceuticals Inc（简称Kalvista）近日宣布，其研发的药物Ekterly®（Sebetralstat）已被正式列入国际儿科遗传性血管性水肿（HAE）治疗指南，作为12岁及以上青少年患者的一线治疗方案。
这一重要进展标志着Ekterly®在青少年HAE治疗领域的临床价值获得国际权威认可。该指南的更新将为全球儿科医生提供明确的治疗依据，有望改善青少年HAE患者的治疗体验和生活质量。
作为一款口服靶向药物，Ekterly®凭借其快速起效和良好的安全性特征，为青少年患者提供了一种便捷、高效的治疗选择。此次纳入指南将进一步巩固Kalvista在罕见病治疗领域的创新地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.